• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ZAFIRLUKAST Drug Record

  • Summary
  • Interactions
  • Claims
  • ZAFIRLUKAST chembl:CHEMBL603 Approved

    Alternate Names:

    ICI-204219
    ACCOLATE
    ZAFIRLUKAST
    4-(5-CYCLOPENTYLOXYCARBONYLAMINO-1-METHYL-1H-INDOL-3-YLMETHYL)-3-METHOXY-N-O-TOLYLSULFONYLBENZAMIDE
    ICI-204,219
    CYCLOPENTYL 3-(2-METHOXY-4-((O-TOLYLSULFONYL)CARBAMOYL)BENZYL)-1-METHYLINDOLE-5-CARBAMATE
    ACCOLATE®
    ZD9188
    chemidplus:107753-78-6
    pubchem.compound:5717
    chembl:CHEMBL603
    drugbank:00549
    rxcui:114970

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antiasthmatic agent
    Drug Class anti-asthmatic agents
    Year of Approval 1996
    (3 More Sources)

    Publications:

    Cazzola et al., 2000, Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist., Pulm Pharmacol Ther
    Heise et al., 2000, Characterization of the human cysteinyl leukotriene 2 receptor., J. Biol. Chem.
    O'Byrne, 1997, Leukotrienes in the pathogenesis of asthma., Chest
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Wang et al., 2000, A novel hepatointestinal leukotriene B4 receptor. Cloning and functional characterization., J. Biol. Chem.
    Murata et al., 2002, [Zafirlukast (Accolate): a review of its pharmacological and clinical profile]., Nippon Yakurigaku Zasshi
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Lee HJ et al., 2016, Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast., Arch Pharm Res
  • ZAFIRLUKAST   CYSLTR1

    Interaction Score: 4.86

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Cysteinyl leukotriene receptor 1 antagonist
    Direct Interaction yes
    Trial Name zafirlukast,Accolate

    PMIDs:
    11061985 10851239 9042024 11752352 11006272 11979731


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • ZAFIRLUKAST   CYP2C9

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 27377818


    Sources:
    DTC PharmGKB

  • ZAFIRLUKAST   KAT2A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ZAFIRLUKAST   MAPK1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ZAFIRLUKAST   POLB

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ZAFIRLUKAST   USP1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ZAFIRLUKAST   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • ZAFIRLUKAST   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • ZAFIRLUKAST   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • ZAFIRLUKAST   BAZ2B

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ZAFIRLUKAST   VDR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ZAFIRLUKAST   GMNN

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ZAFIRLUKAST   NFE2L2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ZAFIRLUKAST   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: ZAFIRLUKAST

    • Version: 01-August-2011

    Alternate Names:
    ZAFIRLUKAST Primary Drug Name

    Drug Info:
    Year of Approval 1996
    Drug Class anti-asthmatic agents

    Publications:

  • TdgClinicalTrial: ZAFIRLUKAST

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiasthmatic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • DTC: ZAFIRLUKAST

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL603 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • PharmGKB: zafirlukast

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Lee HJ et al., 2016, Effects of CYP2C9 genetic polymorphisms on the pharmacokinetics of zafirlukast., Arch Pharm Res

  • TTD: Zafirlukast

    • Version: 2020.06.01

    Alternate Names:
    D05DVP TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL603

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL603

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21